Google shares framework for safer AI in health to boost trust and oversight
Google has published a framework for evaluating AI in health, focusing on accuracy, safety and usefulness. This move aims to set standards for the sector and guide regulated organisations. Senior leaders should assess how such frameworks affect compliance and risk.
US Congress faces deadline to fund expiring health care programmes
Congress must act to fund health care programmes like Medicaid and Medicare before Democrats take control, according to STAT. Delays could affect insurers and healthcare groups relying on federal funding. Leaders should watch for last-minute changes or lapses.
Sanders may use FDA funding bill to push for pharma reforms
Bernie Sanders could use his influence on the FDA funding bill to seek reforms, according to STAT. Pharma and biotech leaders may face new regulatory proposals or cost controls. Senior executives should monitor developments for potential operational impact.
3M sets $7.35 billion for PFAS personal injury claims, easing litigation risk
3M will pay $7.35 billion over nine years to settle nearly all PFAS-related personal injury claims. This move reduces litigation uncertainty for insurers and healthcare firms exposed to chemical liability. Ongoing environmental claims remain a risk to monitor.
CVS Health to separate pharmacy and insurance units amid regulatory pressure
CVS Health plans to split its pharmacy and insurance businesses, according to STAT. The move follows increased scrutiny of vertical integration by federal and state authorities. Health insurers and pharma leaders should watch for shifts in deal strategy and regulatory focus.
MultiCare and Samaritan merge, plan $700 million investment in facilities and tech
MultiCare and Samaritan have merged, with MultiCare set to invest $700 million in Samaritan’s facilities and technology. Senior healthcare leaders should note the scale of planned upgrades and the regulatory approval involved. Watch for how the investment shapes regional care delivery.
Servier’s $1.55 billion muscular dystrophy drug fails key clinical trial
Servier reported a setback for its $1.55 billion drug in a major muscular dystrophy trial. This raises questions for pharma leaders about risk in rare disease pipelines. Watch for how Servier and peers adjust rare disease strategies.
Most Americans reject AI-only decisions in healthcare and insurance
A Pew Research Center report says 60% of US adults are uneasy with AI in medical diagnosis or treatment decisions. Only 5% are open to AI-only insurance claim decisions. Insurers and healthcare leaders face ongoing public distrust and must address transparency and consent.
Democrats gain Senate control, raising uncertainty for Trump-era health policies
Democrats have secured Senate control, giving them the ability to challenge Trump-era health care actions. This shift could affect regulatory priorities for healthcare and pharma leaders. Watch for policy changes that may alter compliance or market strategies.
FDA and CMS seek state partnerships on AI regulation and liability in healthcare
Federal officials plan to work with states on regulating AI and protecting doctors from AI liability, according to STAT. This move could reshape how AI tools are governed and used in healthcare. Senior leaders should watch for new compliance and risk frameworks.
US clinics bill urgent care as ER, raising costs for patients
STAT reports that some US clinics are billing urgent care visits as emergency room care, leading to higher charges for patients. This practice affects affordability and raises questions for insurers and providers. Watch for policy changes or insurer responses.
KFF says Medicare Part D premiums to rise 50% on average next year
KFF reports a 50% average increase in Medicare Part D premiums for 2025. Health insurers and policy leaders face higher costs and consumer pressure. Senior executives should monitor enrolment trends and prepare for member questions.
NHS claims on Palantir AI platform disputed by 29 hospital trusts
The Guardian reports that 29 NHS trusts listed as benefiting from Palantir’s £330m AI data platform say they are not using it or its applications. This raises questions about AI adoption claims and the accuracy of NHS reporting for regulated healthcare leaders.
FDA approves generic HIV prevention shot for global access
The FDA has approved a generic HIV prevention shot, aiming to expand access in lower-income countries. This move could affect drug pricing and public health policy for pharma and healthcare leaders. Watch for changes in procurement and global health strategy.
AMA says AI vendors and health systems share liability for clinical AI
The AMA has set out that physicians, AI developers and healthcare organisations each hold responsibility for clinical AI. This widens the scope of liability in patient care. Healthcare leaders should review risk and compliance processes now.
Four drugmakers accused of paying millions to Russian middlemen for drug supply
STAT reports that four major drugmakers allegedly paid tens of millions to middlemen to supply lifesaving drugs to Russian government entities. This raises compliance and reputational risks for pharma leaders. Firms may need to review third-party controls and due diligence.
AI governance in high-risk sectors risks sidelining human judgement
AI governance frameworks in high-risk industries may weaken proactive human judgement, according to MIT Sloan Management Review. For banks, insurers and healthcare leaders, this could mean missing early signals of risk. Firms should review how decision authority is distributed.
US Republicans join Democrats in targeting CVS over drug prices
Republicans have joined Democrats in criticising pharmacy groups like CVS for high drug prices, according to Politico. This signals growing bipartisan scrutiny of pharmacy benefit managers. Senior healthcare and pharma leaders should expect more regulatory attention.
CVS sues to avoid $2B loss from Medicare Advantage ratings drop
CVS has filed a lawsuit to prevent a $2 billion financial hit from lower Medicare Advantage star ratings, according to Healthcare Dive. The case signals growing legal pushback from insurers over rating changes. Senior healthcare leaders should monitor legal outcomes and regulatory responses.
US judge says federal agency overreached on Medicaid work rules
A federal judge found regulators went too far in limiting exceptions to Medicaid work requirements. This affects health insurers and providers managing compliance risk. Watch for further legal and policy shifts on Medicaid eligibility rules.